Table 3.
Visual MRI assessment associated with DSS and DFS at univariate analysis
| DSS status | DFS status | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable |
Breast cancer death* (n = 7) |
No Breast cancer death* (n = 33) | HR (95% CI) | p- value |
Recurrence* (n = 12) |
No recurrence* (n = 28) |
HR (95% CI) | p- value |
| Mass shape | ||||||||
| Round or oval | 0 (0.0) | 13 (39.4) | 1 | 1 (8.3) | 12 (42.9) | 1 | ||
| Irregular | 7 (100.0) | 20 (60.6) | 40.01 (0.06–27250.12) | 0.728 | 11 (91.7) | 16 (57.1) | 2.34 (0.51–10.71) | 0.274 |
| Mass margin | ||||||||
| Circumscribed | 0 (0) | 9 (27.2) | 1 | 0 (0.0) | 9 (32.1) | 1 | ||
| Not circumscribed | 7 (100.0) | 24 (72.8) | 32.68 (0.03–42314.51) | 0.340 | 12 (100.0) | 19 (67.9) | 33.25 (0.15–7489.42) | 0.205 |
| Internal enhancement | ||||||||
| Heterogeneous | 4 (57.1) | 9 (27.2) | 1 | 5 (41.7) | 8 (28.6) | 1 | ||
| Rim enhancement | 3 (42.9) | 24 (72.8) | 3.06 (0.68–13.73) | 0.145 | 7 (58.3) | 20 (71.4) | 1.60 (0.51–5.05) | 0.423 |
| Intratumoral signal hyperintensity on T2WI | ||||||||
| Absent | 3 (42.9) | 24 (72.8) | 1 | 6 (50.0) | 21 (75.0) | 1 | ||
| Present | 4 (57.1) | 9 (27.2) | 2.70 (0.61–12.5) | 0.191 | 6 (50.0 | 7 (25.0) | 2.38 (0.76–7.14) | 0.138 |
| Peritumoral edema | ||||||||
| Absent | 2 (28.6) | 16 (48.5) | 1 | 3 (25.0) | 15 (53.6) | 1 | ||
| Present | 5 (71.4) | 17 (51.5) | 1.95 (0.38–10.10) | 0.425 | 9 (75.0) | 13 (46.4) | 2.70 (0.74–10.00) | 0.132 |
CI, confidence interval; DFS, disease-free survival; DSS, disease-specific survival; HR, hazard ratio;T2WI, T2 weighted imaging.
*Data are the numbers of patients, with percentages in parentheses.